THE CASUAL ROLE OF VITAMIN D SUPPLEMENTATION IN THE COVID-RELATED HEALTH OUTCOMES (RETROSPECTIVE CROSS-SECTION STUDY)
DOI:
https://doi.org/10.52340/jecm.2024.05.05Ключевые слова:
COVID-19, Hospitalization, Oxygen Therapy, Glucocorticoids, Vitamin DАннотация
The aim of our study was to investigate the causal role of vitamin D supplementation in the COVID-related health outcomes (hospitalization, transfer to ICU unit, requirement of oxygen therapy, the treatment by glucocorticoids) of the patients with SARS infection.
Methods. Presented retrospective cross-section study was performed based on the data of National Center of Disease control and Public Health (NCDC) of Georgia. 475 records of the patients with determined serum 25-hydroxivitamin D [25(OH)D] were randomly selected for the study. Researchers provided the visits of these patients and after obtaining the written informed consent 384 persons from the NCDC database have been included in the study group. Study subjects were divided by the presence of vitamin D supplementation before SARS-virus was confirmed: the group 1 – patients with vitamin D supplementation – n=224; the group 2 – patients without vitamin D supplementation – n=160. The patients were surveyed by the special structured questionnaires to provide the information about the presence of vitamin D supplementation before the SARS-virus confirmation.
Results. Mean level of serum 25-hydroxivitamin D [25(OH)D] in the study group 1 was 22.5±9.9 ng/ml, and in the study group 2 was 16.9±8.2 ng/ml; The difference of these values between the groups was significant - t=5.861, p<0.001. The odds of hospitalization in the group 2 were 3.6 times higher compared to group 1 (OR = 3.60, 95%CI 1.85 – 7.03, F-test = 3.76, p<0.001). The odds of the requirement of transfer to ICU unit (OR = 0.93, 95%CI 0.15 – 5.65, F-test = 0.08, p=0.939), the requirement of oxygen therapy (OR = 1.66, 95%CI 0.86 – 6.65, F-test = 1.66, p=0.097), and the treatment by glucocorticoids (OR = 1.41, 95%CI 0.49 – 4.13, F-test = 0.64, p=0.521) between the groups were not significant.
Conclusion. Vitamin D supplementation was associated with 3.6-fold lower risk of hospitalization due to SARS-CoV-2 infection. Therefore, COVID-19-related morbidity was associated with the decreased serum 25(OH)D levels. Future studies should also investigate any potential role of vitamin D sufficiency in the prevention of SARS-CoV-2 infection and mortality. Notably, the relation between vitamin D sufficiency and infection with various strains of SARS-CoV-2 requires paying the special attention.
Скачивания
Библиографические ссылки
World Health Organization (WHO) Coronavirus disease (COVID-19) pandemic. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Wang L., Wang Y., Ye D., Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55(6):105948.
Chen N., Zhou M., Dong X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
Team C Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States, February 12–March 16, 2020. Morb Mortal Wkly Rep. 2020;69(12):343–346.
Mahase E. Covid-19: why are age and obesity risk factors for serious disease? BMJ. 2020;371:m4130.
Tramontana F., Napoli N., El-Hajj Fuleihan G., Strollo R. The D-side of COVID-19: musculoskeletal benefits of vitamin D and beyond. Endocrine. 2020;69(2):237–240.
Anker M.S., Landmesser U., von Haehling S., Butler J., et al. Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers. J Cachexia Sarcopenia Muscle. 2021;12(1):9–13.
Di Filippo L., De Lorenzo R., D’Amico M., Sofia V., Roveri L., et al. COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: a post-hoc analysis of a prospective cohort study. Clin Nutr. 2021 Apr; 40(4): 2420–2426
Roth D.E., Abrams S.A., et al. Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low- and middle-income countries. Ann N Y Acad Sci. 2018;1430(1):44–79.
Bouillon R., Carmeliet G. Vitamin D insufficiency: definition, diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2018;32(5):669–684.
Vanlint S. Vitamin D and obesity. Nutrients. 2013;5(3):949–956.
Grant W.B., Lahore H., McDonnell S.L., Baggerly C.A., et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020;12(4):988.
Ilie P.C., Stefanescu S., Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res. 2020;32(7):1195–1198.
Rhodes J.M., Subramanian S., Laird E., Kenny R.A. Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity. Aliment Pharmacol Ther. 2020;51(12):1434–1437.
Bouillon R., Marcocci C., Carmeliet G., Bikle D., et al. Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev. 2018;40(4):1109–1151.
Aranow C. Vitamin D and the immune system. J Investig Med. 2011;59(6):881–886.
Greiller C.L., Martineau A.R. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. 2015;7(6):4240–4270.
Tay M.Z., Poh C.M., Rénia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–374.
Martineau A.R., Jolliffe D.A., et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356.
Jolliffe D., Camargo C.A., Sluyter J., Aglipay M., Aloia J., Bergman P., et al. Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol. 2021 May:9(5):276-292.
Chakhtoura M., Napoli N., El Hajj Fuleihan G. Commentary: myths and facts on vitamin D amidst the COVID-19 pandemic. Metabolism. 2020; 109:154276.
Grant W.B., Lahore H., Rockwell M.S. The benefits of vitamin D supplementation for athletes: better performance and reduced risk of COVID-19. Nutrients. 2020;12(12):3741.
National Health Service Vitamin D. https://www.nhs.uk/conditions/vitamins-and-minerals/vitamin/d
Griffin G., Hewison M., Hopkin J., Kenny R.A., Quinton R., Rhodes J., et al. Preventing vitamin D deficiency during the COVID-19 pandemic: UK definitions of vitamin D sufficiency and recommended supplement dose are set too low. Clin Med (Lond) 2021;21(1):e48–e51.
National Institute for Health and Care Excellence (NICE) COVID-19 rapid evidence summary: vitamin D for COVID-19. 2020. https://www.nice.org.uk/guidance/ng187
ASBMR, Endocrine Society, ECTS, NOF, IOF Joint guidance on vitamin D in the era of COVID-19 from the ASBMR, AACE, Endocrine Society, ECTS, NOF, and IOF. 2020. https://www.endocrine.org/news-and-advocacy/news-room/2020/joint-guidance-on-vitamin-d
Holick MF. Cancer, sunlight and vitamin D. J Clin Transl Endocrinol. 2014;1(4):179-186.
Bilezikian JP, Bikle D, Hewison M, et al. MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19. Eur J Endocrinol. 2020;183(5):R133-R147.
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
